会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 21. 发明授权
    • 3(2H)Pyridazinone, process for its preparation and anti-allergic agent
containing it
    • 3(2H)哒嗪酮,其制备方法和含有它的抗过敏剂
    • US4892947A
    • 1990-01-09
    • US854521
    • 1986-04-22
    • Motoo MutsukadoKeizo TanikawaKen-ichi ShikadaRyozo Sakoda
    • Motoo MutsukadoKeizo TanikawaKen-ichi ShikadaRyozo Sakoda
    • A61K31/50C07D237/22
    • A61K31/50C07D237/22
    • A 3(2H)pyridazinone of the formula: ##STR1## wherein R.sub.1 is hydrogen, methyl, C.sub.3 -C.sub.6 alkenyl, C.sub.5 or C.sub.6 cycloalkyl, benzyl, phenyl, --(CH.sub.2).sub.m CO.sub.2 R.sub.3 (wherein R.sub.3 is hydrogen or C.sub.1 -C.sub.5 alkyl, and m is an integer of from 1 to 4), --(CH.sub.2).sub.n A (wherein A is --OH or --N(R.sub.4).sub.2 wherein R.sub.4 is C.sub.1 -C.sub.3 alkyl, and n is an integer of from 2 to 6) or --CH.sub.2 CF.sub.3 ; R.sub.2 is chlorine or bromine; each of Y.sub.1 and Y.sub.2 which may be the same or different, is hydrogen, C.sub.1 -C.sub.5 alkyl, C.sub.2 -C.sub.8 alkenyl, halogen, --OR.sub.5 (wherein R.sub.5 is hydrogen, C.sub.1 -C.sub.8 alkyl or ##STR2## wherein q is an integer of from 1 to 4), --CO.sub.2 R.sub.6 (wherein R.sub.6 is hydrogen or C.sub.1 -C.sub.5 alkyl), --N(R.sub.7).sub.2 (wherein R.sub.7 is C.sub.1 -C.sub.4 alkyl) or --SR.sub.8 (wherein R.sub.8 is C.sub.1 -C.sub.4 alkyl); and Y.sub.3 is C.sub.1 -C.sub.5 alkyl, C.sub.2 -C.sub.8 alkenyl, halogen, --OR.sub.5 (wherein R.sub.5 is as defined above), --CO.sub.2 R.sub.6 (wherein R.sub.6 is as defined above), --N(R.sub.7).sub.2 (wherein R.sub.7 is as defined above) or --SR.sub.8 (wherein R.sub.8 is as defined above), or a pharmaceutically acceptable salt thereof.
    • 具有下式的3(2H)哒嗪酮:其中R 1是氢,甲基,C 3 -C 6烯基,C 5或C 6环烷基,苄基,苯基, - (CH 2)m CO 2 R 3(其中R 3是氢或C1- C5烷基,m为1〜4的整数), - (CH2)nA(其中A为-OH或-N(R4)2,其中R4为C1-C3烷基,n为2〜 6)或-CH 2 CF 3; R2是氯或溴; 可以相同或不同的Y 1和Y 2各自为氢,C 1 -C 5烷基,C 2 -C 8烯基,卤素,-OR 5(其中R 5为氢,C 1 -C 8烷基或其中q为 1至4),-CO 2 R 6(其中R 6是氢或C 1 -C 5烷基),-N(R 7)2(其中R 7是C 1 -C 4烷基)或-SR 8(其中R 8是C 1 -C 4烷基); 并且Y 3是C 1 -C 5烷基,C 2 -C 8烯基,卤素,-OR 5(其中R 5如上定义),-CO 2 R 6(其中R 6如上定义),-N(R 7)2(其中R 7如上所述 )或-SR 8(其中R8如上定义)或其药学上可接受的盐。